In a recent review published in the journal Nutrients, researchers in Italy discussed the potential pathophysiological mechanisms of the low FODMAP (fermentable oligosaccharide, disaccharide, monosaccharide, and polyol) diet in managing irritable bowel syndrome (IBS). They provide an overview of the current evidence, exploring the optimal application of the diet as well as the challenges associated with implementing the low FODMAP diet for IBS.
Review: The Role of the FODMAP Diet in IBS. Image Credit: Marharyta M / Shutterstock
Background
IBS is a common gut-brain interaction disorder, affecting 3.8% to 12% of the population, and is more prevalent in females. Diagnosis involves excluding organic causes through specific tests. IBS manifests as chronic abdominal pain associated with defecation and altered bowel habits, categorized into subtypes. Recent insights highlight immune activation and compromised gut barrier in its pathophysiology. Traditional drug therapies show limited efficacy, prompting patients to explore alternative approaches, with over 80% noting connections to food. The low FODMAP diet emerges as an evidence-backed intervention with two methods for implementation: top-down and bottom-up. Researchers in the present review provide a comprehensive guide to FODMAP diets in IBS, discussing mechanisms, optimal settings, and potential disadvantages, aiming to aid clinicians in improving clinical outcomes and quality of life.
The low FODMAP diet
The term FODMAP was coined to categorize fermentable carbohydrates linked to gastrointestinal symptoms, especially in individuals with IBS. Evidence prior to this concept connected poorly absorbed short-chain carbohydrates to IBS symptoms. The first trial that confirmed the efficacy of a low fructose/fructan diet was conducted in 2006, demonstrating symptom relief and fructose malabsorption in individuals with IBS. Mechanistic investigations in 2010 explored FODMAP effects in an ileostomy model while measuring breath hydrogen levels and revealed that osmotic and fermentative properties of FODMAP contribute to the symptoms.
The latest low FODMAP diet includes six carbohydrates and aims to reduce overall FODMAP consumption. FODMAPs show three common functional properties: low absorption in the small intestine, rapid bacterial fermentation, and osmotically active molecules. Mechanisms proposed for FODMAP-induced symptoms include luminal distention by gas and water, visceral hypersensitivity, increased intestinal permeability, microbiota alterations, SCFA production, and motility changes. However, the precise interplay of these mechanisms in the context of IBS and the low FODMAP diet remains a complex and evolving area of research, necessitating further exploration to enhance our understanding of the role of FODMAPs in IBS pathophysiology and dietary management.
Symptom improvement with the diet
Low FODMAP diet has gained popularity over the years as a dietary intervention for IBS due to the positive outcomes observed in numerous trials. Implementation of the approach involves restricting fermentable carbohydrates. Studies highlight the efficacy of this approach in alleviating symptoms such as bloating, pain, and changes in stool frequency. Approximately 65% of patients with carbohydrate malabsorption, particularly fructose intolerance, showed symptom improvement after a month of dietary restriction. Various international guidelines recommend the low FODMAP diet as a second-line treatment for IBS, acknowledging its potential benefits. Comparative studies indicate the superiority of the low FODMAP diet over other dietary approaches and suggest its effectiveness in improving overall gastrointestinal symptoms.
However, concerns about complexity, cost, and nutritional adequacy necessitate the involvement of trained dietitians in the application of a low FODMAP diet for IBS. Personalization and a stepwise reintroduction of FODMAPs could further enhance adaptability and long-term adherence, providing patients with a tailored approach to managing IBS symptoms.
Response markers
Studies on the low FODMAP diet's effectiveness in IBS primarily report success rates of 50-75%. Efforts to enhance efficacy and identify predictors of response include a recent crossover trial, which suggests that responders tend to have a more severe IBS profile and higher anxiety levels at baseline. Potential predictors include breath test results, with a positive FODMAP meal challenge test showing promise in forecasting diet response. Microbiota analyses reveal associations between specific bacterial taxa and positive responses, emphasizing the role of the gut microenvironment. Fecal and urinary metabolites, particularly volatile organic compounds, show promise in distinguishing responders, but further research is needed for validation and clarity.
Challenges
Despite its effectiveness in alleviating symptoms, the low FODMAP diet remains associated with several challenges and limitations. Social and lifestyle difficulties, including expense and impact on quality of life, are noted, with traditional dietary advice deemed more cost-effective and practical. Nutritional deficiencies, especially in fiber and vitamins, raise concerns, requiring monitoring by healthcare professionals. Microbiota alterations particularly reduced Bifidobacterium, pose potential long-term risks. Additionally, there are challenges such as those in precisely quantifying FODMAP content, potential exacerbation of constipation, links to eating disorders, and limited long-term data. While some studies report sustained benefits, more research on the diet's long-term efficacy and safety is needed.
Conclusion
In conclusion, the low FODMAP diet is a promising strategy for managing IBS symptoms. Although the approach is effective and customizable, research gaps exist, particularly in microbiome implications and long-term effects. The researchers highlight the importance of undertaking the diet under medical guidance. Further research is needed to confirm the long-term implications and benefits of the low FODMAP diet.
Korean fermented food Doenjang shows promise in alleviating menopausal symptoms